10x Genomics (TXG) Competitors $13.32 -0.25 (-1.84%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends TXG vs. CTKB, EYPT, LAB, PACB, QTRX, NAUT, SEER, AKYA, HBIO, and BLIShould you be buying 10x Genomics stock or one of its competitors? The main competitors of 10x Genomics include Cytek Biosciences (CTKB), EyePoint Pharmaceuticals (EYPT), Standard BioTools (LAB), Pacific Biosciences of California (PACB), Quanterix (QTRX), Nautilus Biotechnology (NAUT), Seer (SEER), Akoya Biosciences (AKYA), Harvard Bioscience (HBIO), and Berkeley Lights (BLI). These companies are all part of the "analytical instruments" industry. 10x Genomics vs. Cytek Biosciences EyePoint Pharmaceuticals Standard BioTools Pacific Biosciences of California Quanterix Nautilus Biotechnology Seer Akoya Biosciences Harvard Bioscience Berkeley Lights Cytek Biosciences (NASDAQ:CTKB) and 10x Genomics (NASDAQ:TXG) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, community ranking, dividends, media sentiment, risk, valuation and institutional ownership. Is CTKB or TXG more profitable? Cytek Biosciences has a net margin of -5.05% compared to 10x Genomics' net margin of -28.93%. Cytek Biosciences' return on equity of -2.58% beat 10x Genomics' return on equity.Company Net Margins Return on Equity Return on Assets Cytek Biosciences-5.05% -2.58% -2.05% 10x Genomics -28.93%-25.07%-19.41% Do institutionals & insiders believe in CTKB or TXG? 69.5% of Cytek Biosciences shares are held by institutional investors. Comparatively, 84.7% of 10x Genomics shares are held by institutional investors. 9.6% of Cytek Biosciences shares are held by company insiders. Comparatively, 10.0% of 10x Genomics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media favor CTKB or TXG? In the previous week, Cytek Biosciences had 1 more articles in the media than 10x Genomics. MarketBeat recorded 6 mentions for Cytek Biosciences and 5 mentions for 10x Genomics. Cytek Biosciences' average media sentiment score of 0.65 beat 10x Genomics' score of 0.62 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive 10x Genomics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, CTKB or TXG? Cytek Biosciences has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.87, suggesting that its share price is 87% more volatile than the S&P 500. Does the MarketBeat Community believe in CTKB or TXG? 10x Genomics received 34 more outperform votes than Cytek Biosciences when rated by MarketBeat users. Likewise, 52.94% of users gave 10x Genomics an outperform vote while only 45.45% of users gave Cytek Biosciences an outperform vote. CompanyUnderperformOutperformCytek BiosciencesOutperform Votes2045.45% Underperform Votes2454.55% 10x GenomicsOutperform Votes5452.94% Underperform Votes4847.06% Do analysts recommend CTKB or TXG? Cytek Biosciences presently has a consensus price target of $9.17, suggesting a potential upside of 49.54%. 10x Genomics has a consensus price target of $29.19, suggesting a potential upside of 119.13%. Given 10x Genomics' higher possible upside, analysts clearly believe 10x Genomics is more favorable than Cytek Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cytek Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.0010x Genomics 1 Sell rating(s) 7 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.53 Which has higher valuation and earnings, CTKB or TXG? Cytek Biosciences has higher earnings, but lower revenue than 10x Genomics. Cytek Biosciences is trading at a lower price-to-earnings ratio than 10x Genomics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCytek Biosciences$201.21M3.92-$12.15M-$0.08-76.6310x Genomics$629.74M2.56-$255.10M-$1.53-8.71 Summary10x Genomics beats Cytek Biosciences on 10 of the 19 factors compared between the two stocks. Ad Priority GoldJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purposely crash the bond market to sabotage Trump's comeback.Get your free guide NOW before it's too late. Get 10x Genomics News Delivered to You Automatically Sign up to receive the latest news and ratings for TXG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TXG vs. The Competition Export to ExcelMetric10x GenomicsAnalytical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.61B$5.07B$5.03B$8.81BDividend YieldN/A0.46%5.16%4.06%P/E Ratio-8.7123.87135.4117.82Price / Sales2.564.391,160.9774.56Price / CashN/A40.7033.5332.53Price / Book2.142.084.674.68Net Income-$255.10M$515,312.50$119.07M$226.08M7 Day Performance-5.67%-5.56%-1.83%-1.04%1 Month Performance-13.34%-8.12%-3.60%1.04%1 Year Performance-68.89%-17.04%31.66%26.28% 10x Genomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TXG10x Genomics4.6868 of 5 stars$13.32-1.8%$29.19+119.1%-69.3%$1.64B$618.73M-8.711,259CTKBCytek Biosciences3.2393 of 5 stars$6.13flat$9.17+49.5%+0.8%$789.61M$201.21M-76.63500Short Interest ↓EYPTEyePoint Pharmaceuticals2.4787 of 5 stars$8.96-2.8%$28.00+212.7%+26.6%$628.59M$46.02M0.00120LABStandard BioTools3.2161 of 5 stars$1.61+6.6%$2.88+78.6%-29.1%$562.11M$106.34M0.00620PACBPacific Biosciences of California1.846 of 5 stars$1.72flat$3.63+110.8%-80.0%$471.05M$200.52M0.00730Analyst RevisionQTRXQuanterix2.4262 of 5 stars$11.02-0.4%$23.25+111.0%-52.5%$424.47M$122.37M0.00460NAUTNautilus Biotechnology1.7412 of 5 stars$2.34+4.5%$4.50+92.3%-15.8%$293.82MN/A-4.18130SEERSeer2.1697 of 5 stars$2.29+0.4%$3.00+31.0%+30.9%$134.44M$16.66M0.00160AKYAAkoya Biosciences1.6888 of 5 stars$2.16flat$5.43+151.3%-50.8%$107.06M$86.82M-1.8390Analyst ForecastHBIOHarvard Bioscience1.566 of 5 stars$2.16+5.4%N/A-48.8%$89.41M$112.25M0.00490Positive NewsBLIBerkeley Lights0.7786 of 5 starsN/AN/AN/A$72.04M$78.60M-0.70293 Related Companies and Tools Related Companies Cytek Biosciences Alternatives EyePoint Pharmaceuticals Alternatives Standard BioTools Alternatives Pacific Biosciences of California Alternatives Quanterix Alternatives Nautilus Biotechnology Alternatives Seer Alternatives Akoya Biosciences Alternatives Harvard Bioscience Alternatives Berkeley Lights Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TXG) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
